Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04884477 · ClinicalTrials.gov registry record

COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

A clinical trial of COVID-19 and Convalescent Plasma, sponsored by Mayo Clinic.

Completed
Registry status
342
Enrollment target
1
Study location

NCT04884477 is a study of COVID-19 and Convalescent Plasma that has completed, run by Mayo Clinic. The registered enrollment target is 342 participants, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04884477, a study of COVID-19 and Convalescent Plasma, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
342 participants
Enrollment target
1
Study location

Study Summary

This study is being conducted to determine if patients with compromised B-cell function due to anti-CD20 therapy and newly diagnosed COVID-19 infection benefit from convalescent plasma.

Interventions

  • BIOLOGICAL Convalescent Plasma

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 342 participants
Start Date 2021-06-01
Est. Completion 2023-01-15

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT04884477

The ClinicalTrials.gov registry entry for NCT04884477 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 342 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (99% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Convalescent Plasma is the first listed.

NCT04884477 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT04884477 about?

NCT04884477 is a clinical study titled "COVID-19 Infection in Patients Receiving Anti-CD20 Therapy". This study is being conducted to determine if patients with compromised B-cell function due to anti-CD20 therapy and newly diagnosed COVID-19 infection benefit from convalescent plasma.

What is the current status of trial NCT04884477?

This trial is currently completed. The enrollment target is 342 participants. The study started on 2021-06-01. Estimated completion is 2023-01-15.

What conditions does trial NCT04884477 study?

This clinical trial studies the following conditions: COVID-19, Convalescent Plasma, Immunosuppressed Host, Anti-CD20 Therapy.

What interventions are being tested in trial NCT04884477?

The interventions under investigation include: Convalescent Plasma (BIOLOGICAL).

Who is sponsoring clinical trial NCT04884477?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04884477 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.